
|Articles|April 26, 2016 (Updated: November 15, 2020)
Disease Interception and the US National Cancer Moonshot
Author(s)DIA
April 26, 2016.
Advertisement
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
2
Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion
3
FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria
4
Real-World Data Brings New Insights to Natural History of Disease Studies
5




